New Biomarker for Liver Cancer Identified

Scientists have discovered a new potential biomarker for hepatocellular carcinoma (HCC), the most common type of primary liver cancer.

Aging-US published "Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma" which reported that there is still a lack of comprehensive analysis of the circular RNA -long non-coding RNA -miRNA-mRNA ceRNA network in hepatocellular carcinoma.

Current Treatments for Liver Cancer | Hepatoma | Hepatocellular Carcinoma
Current Treatments for Liver Cancer (also known as hepatoma or hepatocellular carcinoma) can result in complete cure of the disease if it is detected early.

‘The network, revealed in the Aging-US study, may help comprehensively elucidate the ceRNA mechanisms driving hepatocellular carcinoma (HCC), and provide novel candidate biomarkers for evaluating the prognosis of HCC.’

Tweet it Now

Then, the HCC prognostic circRNA-lncRNA-miRNA-mRNA ceRNA network was established.

The authors constructed a prognostic signature with seven target mRNAs by univariate, lasso and multivariate Cox regression analyses, which yielded 1, 3 and 5-year AUC values of 0.797, 0.733 and 0.721, respectively, indicating its sensitivity and specificity in the prognosis of HCC.

Moreover, the prognostic signature could be validated in GSE14520. The prognostic ceRNA network of 21 circRNAs, 15 lncRNAs, 5 miRNAs, and 7 mRNAs was established according to the targeting relationship between 7 hub mRNAs and other RNAs.

Test Your Knowledge on Liver Cancer
Primary hepatocellular carcinoma is a cancer that starts in the liver. The liver is the largest organ in the body situated in the upper right quadrant of the abdomen. The liver is also a common site for cancer deposits (metastases) from other organs. This is referred to as secondary liver cancer and is more common than primary liver cancer.

Dr. Huifang Liang and Dr. Bixiang Zhang both from The Huazhong University of Science and Technology as well as The Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases said, "HCC, as the most common type of liver cancer, has become one of the main causes of cancer-related death, and it is also a global health problem that has attracted widespread attention."

They described a complicated post-transcriptional regulatory network, in which circRNAs, lncRNAs and other RNAs can compete with miRNAs and act as natural miRNA sponges by virtue of sharing no less than one miRNA response element.

Surgery Possible With Drug Combo for Liver Cancer Patients
Combination therapy could make curative surgery possible for some liver cancer patients who would normally not be considered for the surgery.

Since these noncoding RNAs, and protein-coding mRNAs can combine with miRNAs through MRE, they can compete with miRNAs and participate in the regulation of this complex network.

The RNA sequencing data of TCGA or GEO database can provide circRNA, miRNA and mRNA data of various cancers, which can be an excellent resource for data mining and biological discovery.

COVID-19 First Wave Declined Liver Cancer Care
Liver cancer screening programmes, diagnostic imaging and biopsies, etc. were some of the examples to mention that there has been decline in liver cancer care.

For HCC, prognostic lncRNA-miRNA-mRNA and circRNA-miRNA-mRNA ceRNA networks have been published.

However, there is no research simultaneously including lncRNAs and circRNAs in the ceRNA network of HCC.

The Liang/Zhang Research Team concluded in their Aging-US Research Output, "current research still has some limitations. No in vivo and further in vitro experiments were performed to verify the function of DTYMK in HCC. Additionally, the role of some hub ncRNAs in the prognostic ceRNA network should be verified in future experiments."

Source-Eurekalert